Article
Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations.
BMJ open - 30 Jun 2021
Kondo Takayuki, Banno Haruhiko, Okunomiya Taro, Amino Yoko, Endo Kayoko, Nakakura Akiyoshi, Uozumi Ryuji, Kinoshita Akemi, Tada Harue, Morita Satoshi, Ishikawa Hidehiro, Shindo Akihiro, Yasuda Ken, Taruno Yosuke, Maki Takakuni, Suehiro Takashi, Mori Kohji, Ikeda Manabu, Fujita Koji, Izumi Yuishin, Kanemaru Kazutomi, Ishii Kenji, Shigenobu Kazue, Kutoku Yumiko, Sunada Yoshihide, Kawakatsu Shinobu, Shiota Shunji, Watanabe Toshifumi, Uchikawa Osamu, Takahashi Ryosuke, Tomimoto Hidekazu, Inoue Haruhisa
Abstract excerpt
INTRODUCTION: Alzheimer's disease (AD) is one of the most common causes of dementia. Pathogenic variants in the presenilin 1 (PSEN1) gene are the most frequent cause of early-onset AD. Medications for patients with AD bearing PSEN1 mutation (PSEN1-AD) are limited to symptomatic therapies and no established radical treatments are available. Induced pluripotent stem cell (iPSC)-based drug repurposing identified...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.